Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

BACKGROUND: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing these o...

Descripción completa

Detalles Bibliográficos
Autores principales: Roex, Gils, Timmers, Marijke, Wouters, Kristien, Campillo-Davo, Diana, Flumens, Donovan, Schroyens, Wilfried, Chu, Yiwei, Berneman, Zwi N., Lion, Eva, Luo, Feifei, Anguille, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713173/
https://www.ncbi.nlm.nih.gov/pubmed/33272302
http://dx.doi.org/10.1186/s13045-020-01001-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713173/
https://www.ncbi.nlm.nih.gov/pubmed/33272302
http://dx.doi.org/10.1186/s13045-020-01001-1

Ejemplares similares